Innovative Ocular Therapeutics for China and Global Markets
About Eluminex Biosciences (Suzhou) Limited
We are a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. Our goal is to become a leading global healthcare company in developing the next generation of advanced ocular therapeutics for China and beyond.
The Eluminex mission is to develop the next generation of ocular therapeutics through research and discovery, leveraging advances in the molecular basis of disease.
I am pleased to welcome you to the inaugural website of Eluminex Biosciences. The company was founded in early 2020, aimed at harnessing innovative science to develop the next generation of therapeutic products in ophthalmology for China and global markets.
Eluminex Bioscience is devoted towards innovating the next generation of first-in-class or best-in-class ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases.
It is estimated that in China and India alone, nearly 9 million patients need corneal transplantation. The Eluminex biosynthetic cornea is a novel, genetically engineered biosynthetic cornea using recombinant human collagen protein that is intended to address the shortage of human donor corneas in many other parts of the world including China. Using engineered human protein, the goal is improved long-term clarity without the need for immunosuppressive drugs and to provide sufficient supply of corneal tissue for worldwide demand.